LifeSci Capital Initiates Coverage of BioInvent

Developing Novel Therapeutics for Difficult-To-Treat Cancers with its Antibody Discovery Platform

Report Available here: http://www.lifescicapital.com/equity-research/bioinvent/

NEW YORK, NY / ACCESSWIRE / February 22, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioInvent (Stockholm: BINV.ST), a biopharmaceutical company developing novel therapeutics for difficult-to-treat cancers. The Company utilizes its antibody discovery platform n-CoDeR/F.I.R.S.T to develop oncology candidates with novel mechanisms of action. The Company’s lead clinical candidate, BI-1206, is an antibody that targets FcgRIIB, also known as CD32b. CD32b is expressed in a number of B-cell malignancies and is associated with the development of rituximab resistance. BI-1206 is currently being evaluated in a Phase I/IIa study as both a single-agent, and in combination with rituximab in patients who have relapsed/refractory non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) and express CD32b.

BioInvent’s second asset TB-403 is being evaluated in a Phase I/II study for patients who have relapsed/refractory medulloblastoma, a rare form of brain cancer that primarily affects children. TB-403 is an antibody that targets placental growth factor (PlGF), which has the downstream ability to inhibit neuropilin 1 (Nrp1) mediated signaling. Nrp1 is highly expressed in patients with medulloblastoma, and higher expression is correlated with a poor prognosis.

The Company’s n-CoDeR library contains more than 30 billion fully human antibodies. The F.I.R.S.T screening tool is designed to find antibodies from this library that have activity against cancer-associated targets, while having minimal impact on normal tissues. The most potent antibodies are advanced into preclinical studies. BioInvent has agreements with leading pharmaceutical companies to use its n-CoDeR and F.I.R.S.T platforms. There are 5 ongoing Phase I studies and 4 ongoing preclinical studies with candidates originating from BioInvent’s antibody discovery platform. The advancement of partnered clinical candidates would provide considerable milestone and royalty payments to BioInvent.

In a 43 page Initiation Report LifeSci Capital explains the preclinical and clinical data supporting BI-1206, TB-403, and other clinical candidates. We outline the market opportunity for each indication and discuss the landscape of approved agents and those in development.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioInvent as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 455685